PDF(Pubmed)
Abstract：
UNASSIGNED: The lymphocyte/C-reactive protein (LCR) is a novel immunoinflammatory score and prognostic marker, but the relationship between lymphocyte/C-reactive proteins and clinical outcomes in patients with upper gastrointestinal cancers remains controversial. This study aimed to evaluate the relationship between LCR and the prognosis of upper gastrointestinal cancer by systematic evaluation and meta-analysis.
UNASSIGNED: We systematically searched PubMed, EMBASE, Cochrane, and Web of Science databases to obtain related studies on the relationship between LCR and esophageal cancer (EC), gastric cancer (GC), and esophagogastric junction cancers (EGJ), and used hazard ratio (HR), 95% confidence interval (95%CI) to evaluate the prognostic value of LCR. Outcome measures included overall survival (OS) and disease-free survival (DFS).
UNASSIGNED: Eight retrospective cohort studies with 2838 patients were included. Meta-analysis showed that patients with low LCR cancers had poor overall survival OS and disease-free survival DFS (HR=2.18, 95%CI=1.87-2.55; HR=1.88, 95%CI=1.56-2.26). Subgroup analysis based on cancer type, treatment modality, gender, T stage, TNM stage, country, and LCR threshold showed that lower LCR levels were all associated with worse OS and DFS (P<0.05).
UNASSIGNED: The LCR can be used as a prognostic marker for patients with upper gastrointestinal cancers, and patients with a lower LCR may have a poor prognosis. Due to the limited number of studies included and mostly retrospective studies, the above findings require validation by more high-quality studies.
UNASSIGNED: https://www.crd.york.ac.uk, identifier CRD42023392433.
UNASSIGNED: We systematically searched PubMed, EMBASE, Cochrane, and Web of Science databases to obtain related studies on the relationship between LCR and esophageal cancer (EC), gastric cancer (GC), and esophagogastric junction cancers (EGJ), and used hazard ratio (HR), 95% confidence interval (95%CI) to evaluate the prognostic value of LCR. Outcome measures included overall survival (OS) and disease-free survival (DFS).
UNASSIGNED: Eight retrospective cohort studies with 2838 patients were included. Meta-analysis showed that patients with low LCR cancers had poor overall survival OS and disease-free survival DFS (HR=2.18, 95%CI=1.87-2.55; HR=1.88, 95%CI=1.56-2.26). Subgroup analysis based on cancer type, treatment modality, gender, T stage, TNM stage, country, and LCR threshold showed that lower LCR levels were all associated with worse OS and DFS (P<0.05).
UNASSIGNED: The LCR can be used as a prognostic marker for patients with upper gastrointestinal cancers, and patients with a lower LCR may have a poor prognosis. Due to the limited number of studies included and mostly retrospective studies, the above findings require validation by more high-quality studies.
UNASSIGNED: https://www.crd.york.ac.uk, identifier CRD42023392433.
摘要：
■淋巴细胞/C反应蛋白（LCR）是一种新型的免疫炎症评分和预后指标，但淋巴细胞/C反应蛋白与上消化道肿瘤患者临床结局之间的关系仍存在争议.本研究旨在通过系统评价和荟萃分析评价LCR与上消化道肿瘤预后的关系。
■我们系统地搜索了PubMed，EMBASE,科克伦,和WebofScience数据库，以获得有关LCR与食管癌（EC）之间关系的相关研究，胃癌（GC），和食管胃结合部癌（EGJ），和使用的危险比(HR)，95%可信区间(95CI)评价LCR的预后价值。结果指标包括总生存期（OS）和无病生存期（DFS）。
■纳入了8项回顾性队列研究，共2838例患者。Meta分析显示，低LCR患者总生存OS和无病生存DFS均较差（HR=2.18，95CI=1.87-2.55；HR=1.88，95CI=1.56-2.26）。基于癌症类型的亚组分析，治疗方式，性别,T级,TNM阶段,国家,LCR阈值显示LCR水平降低均与OS和DFS恶化相关(P<0.05)。
■LCR可作为上消化道肿瘤患者的预后指标，LCR较低的患者可能预后不良。由于纳入的研究数量有限，而且大多是回顾性研究，上述发现需要更多高质量研究的验证.
■https://www.crd.约克。AC.英国，标识符CRD42023392433。
■我们系统地搜索了PubMed，EMBASE,科克伦,和WebofScience数据库，以获得有关LCR与食管癌（EC）之间关系的相关研究，胃癌（GC），和食管胃结合部癌（EGJ），和使用的危险比(HR)，95%可信区间(95CI)评价LCR的预后价值。结果指标包括总生存期（OS）和无病生存期（DFS）。
■纳入了8项回顾性队列研究，共2838例患者。Meta分析显示，低LCR患者总生存OS和无病生存DFS均较差（HR=2.18，95CI=1.87-2.55；HR=1.88，95CI=1.56-2.26）。基于癌症类型的亚组分析，治疗方式，性别,T级,TNM阶段,国家,LCR阈值显示LCR水平降低均与OS和DFS恶化相关(P<0.05)。
■LCR可作为上消化道肿瘤患者的预后指标，LCR较低的患者可能预后不良。由于纳入的研究数量有限，而且大多是回顾性研究，上述发现需要更多高质量研究的验证.
■https://www.crd.约克。AC.英国，标识符CRD42023392433。
